BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

148 related articles for article (PubMed ID: 11682325)

  • 1. Adjuvant therapy of malignant melanoma: is there a choice?
    Retsas S
    Crit Rev Oncol Hematol; 2001 Nov; 40(2):187-93. PubMed ID: 11682325
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Adjuvant therapy of malignant melanoma and the role of sentinel node mapping.
    Eggermont AM
    Recent Results Cancer Res; 2000; 157():178-89. PubMed ID: 10857171
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Clinical and histologic involvement of regional lymph nodes in malignant melanoma. Adjuvant vindesine improves survival.
    Retsas S; Quigley M; Pectasides D; Macrae K; Henry K
    Cancer; 1994 Apr; 73(8):2119-30. PubMed ID: 8156517
    [TBL] [Abstract][Full Text] [Related]  

  • 4. What can we learn from phase II adjuvant trials in melanoma?
    Keilholz U; Suciu S; Eggermont AM
    Br J Cancer; 2000 Jul; 83(1):6-7. PubMed ID: 10883660
    [No Abstract]   [Full Text] [Related]  

  • 5. The effect of tamoxifen and cisplatin on the disease-free and overall survival of patients with high risk malignant melanoma.
    McClay EF; McClay ME; Monroe L; Baron PL; Cole DJ; O'Brien PH; Metcalf JS; Maize JC
    Br J Cancer; 2000 Jul; 83(1):16-21. PubMed ID: 10883662
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Adjuvant chemotherapy with dacarbazine, vindesine, and cisplatin in pathological stage II malignant melanoma.
    Pectasides D; Alevizakos N; Bafaloukos D; Tzonou A; Asimakopoulos G; Varthalitis I; Dimitriadis M; Athanassiou A
    Am J Clin Oncol; 1994 Feb; 17(1):55-9. PubMed ID: 8311008
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Low molecular weight heparin treatment for malignant melanoma: a pilot clinical trial.
    Wojtukiewicz MZ; Kozlowski L; Ostrowska K; Dmitruk A; Zacharski LR
    Thromb Haemost; 2003 Feb; 89(2):405-7. PubMed ID: 12574822
    [No Abstract]   [Full Text] [Related]  

  • 8. [Therapy of malignant melanoma at the stage of distant metastasis].
    Garbe C; Eigentler TK
    Hautarzt; 2004 Feb; 55(2):195-213. PubMed ID: 15043023
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Surgical and adjuvant drug therapy in head and neck cutaneous melanoma].
    Hauschild A; Lischner S; Christophers E
    Laryngorhinootologie; 2000 Jul; 79(7):428-33. PubMed ID: 11005097
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Adjuvant treatment with vindesine for metastatic melanoma: in response to the study of Eigentler et al. (2008).
    Retsas S; Quigley M; Pectasides D; Henry K
    Melanoma Res; 2009 Apr; 19(2):123-4. PubMed ID: 19289925
    [No Abstract]   [Full Text] [Related]  

  • 11. [Long-term results of adjuvant chemotherapy after therapeutic lymph node dissection in patients with cutaneous malignant melanoma].
    Kretschmer L; Helmbold P; Emmert S; Marsch WC
    Hautarzt; 2002 Aug; 53(8):536-41. PubMed ID: 12221468
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prospective monitoring of adjuvant treatment in high-risk melanoma patients: lactate dehydrogenase and protein S-100B as indicators of relapse.
    Egberts F; Hitschler WN; Weichenthal M; Hauschild A
    Melanoma Res; 2009 Feb; 19(1):31-5. PubMed ID: 19104452
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Update on the role of adjuvant interferon for high risk melanoma.
    Agarwala SS; Kirkwood JM
    Forum (Genova); 2000; 10(3):230-9. PubMed ID: 11007931
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Fotemustine, dacarbazine, vindesine combination chemotherapy in advanced malignant melanoma: a phase II study of 43 patients.
    Rixe O; Borel C; Paraiso D; Benhammouda A; Petit T; Antoine E; Bizzari JP; Auclerc G; Soubrane C; Weil M
    Melanoma Res; 1995 Dec; 5(6):419-24. PubMed ID: 8589616
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Chemotherapy of malignant melanoma].
    Ishihara K
    Gan To Kagaku Ryoho; 1995 Jan; 22(1):23-7. PubMed ID: 7529980
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Adjuvant therapy in melanoma.
    Mohr P; Weichenthal M; Hauschild A
    Onkologie; 2003 Jun; 26(3):227-33. PubMed ID: 12845206
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Adjuvant chemotherapy in malignant melanoma using dacarbazine, carmustine, cisplatin, and tamoxifen: a University of South Florida and H. Lee Moffitt Melanoma Center Study.
    Saba HI; Cruse CW; Wells KE; Klein CJ; Reintgen DS
    Ann Plast Surg; 1992 Jan; 28(1):60-4. PubMed ID: 1642408
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Adjuvant therapy of malignant melanoma.
    Dickler MN; Coit DG; Meyers ML
    Surg Oncol Clin N Am; 1997 Oct; 6(4):793-812. PubMed ID: 9309094
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Adjuvant use of interferon alpha 2b is not justified in patients with stage IIb/III melanoma.
    Bajetta E
    Nat Clin Pract Oncol; 2008 Jan; 5(1):4-5. PubMed ID: 18043604
    [No Abstract]   [Full Text] [Related]  

  • 20. [Adjuvant chemotherapy as a component of complex treatment for skin melanoma].
    Kudriavtsev DV; Kudriavtseva GT; Mardynskiĭ IuS
    Vopr Onkol; 2008; 54(2):170-7. PubMed ID: 18522165
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.